Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...
The targeted protein degrader BMS-986470 from Bristol Myers Squibb (BMS) boosts levels of fetal hemoglobin in cells, mice, and monkeys, the company reported this weekend at the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results